Lemongrass

Lemongrass contains citral—a monoterpene aldehyde comprising up to 80% of the essential oil—which disrupts microbial cell membranes and activates caspase-3-mediated apoptosis in cancer cell lines, while polyphenols including caffeic acid and syringic acid donate electrons from phenolic hydroxyl groups to scavenge free radicals. In vitro data demonstrate DPPH radical scavenging activity of 80.63 ± 0.49 mg TE/100 mL and antifungal IC₅₀ values of 37 ± 7 µL/L for pure citral against Candida famata, though large-scale human clinical trials remain absent.

Origin & History

Cymbopogon citratus is native to tropical and subtropical regions of South and Southeast Asia, particularly India and Sri Lanka, and has been widely naturalized across the Pacific Islands, Africa, and Latin America. It thrives in well-drained, loamy soils under full sun with warm, humid conditions and elevations up to 900 meters. Across Pacific Island nations including Samoa and Tonga, it is cultivated in home gardens and used extensively in traditional plant medicine.

Historical & Cultural Context

Lemongrass has been used in Ayurvedic medicine in India for centuries as a febrifuge, digestive aid, and treatment for infectious conditions, referenced in traditional Indian materia medica under names such as 'bhustrina.' In Pacific Island communities—including Samoa, Tonga, and Fiji—lemongrass tea has been a foundational home remedy for abdominal pain, fever, and respiratory complaints, often prepared by boiling fresh or dried stalks and sipped warm. African traditional medicine systems similarly employ decoctions of Cymbopogon citratus for hypertension management and as an anxiolytic, reflecting convergent cross-cultural recognition of its pharmacological properties. Lemongrass also holds culinary significance throughout Southeast Asian cooking, particularly Thai and Vietnamese cuisines, where its volatile oils contribute flavor while conferring incidental antimicrobial benefits to food preservation.

Health Benefits

- **Antifungal Activity**: Citral disrupts fungal cell membrane integrity, yielding IC₅₀ values of 37 ± 7 µL/L and MIC values of 142 ± 19 µL/L against Candida famata in vitro, indicating meaningful antifungal potency at low concentrations.
- **Antioxidant Protection**: Polyphenols—primarily caffeic acid (20.81 mg/100 mL) and syringic acid (18.63 mg/100 mL)—donate electrons from phenolic hydroxyl groups, achieving FRAP activity of 1920.92 ± 2.59 mg TE/100 g DW and DPPH scavenging of 80.63 ± 0.49 mg TE/100 mL.
- **Digestive Support (Traditional)**: Samoan and Tongan traditional medicine prepares lemongrass tea specifically for stomachache relief, likely mediated by spasmolytic terpenoids and volatile oils that relax gastrointestinal smooth muscle.
- **Anxiolytic Potential**: Alkaloids, flavonoids such as apigenin and luteolin, and terpenoids in lemongrass are proposed to modulate GABAergic pathways in preclinical models, though human trials are not yet established.
- **Anti-inflammatory and Antinociceptive Effects**: Terpenoids including β-myrcene and geraniol, alongside quercetin and kaempferol, inhibit pro-inflammatory mediator production and reduce nociceptive signaling in animal studies.
- **Antimicrobial Properties**: Propionic acid and citral together inhibit a broad spectrum of bacteria and fungi by disrupting membrane function and interfering with enzyme activity, supporting traditional uses for infection-related complaints.
- **Potential Anti-diabetic Activity**: Flavonoids such as isoorientin 2'-O-rhamnoside and luteolin are proposed to inhibit α-glucosidase and modulate insulin signaling pathways, based on in vitro and animal-model evidence.

How It Works

Citral, the principal bioactive constituent, functions as an α,β-unsaturated monoterpene aldehyde that activates caspase-3-dependent apoptotic cascades, producing characteristic DNA fragmentation in hematopoietic and ovarian cancer cell lines in vitro. In microbial systems, citral intercalates into phospholipid bilayers of fungal and bacterial membranes, increasing permeability and causing leakage of intracellular contents, with IC₅₀ of 177 ± 19 µL/L against Candida famata for the whole essential oil. Phenolic compounds—caffeic acid, syringic acid, quercetin, and luteolin—donate hydrogen atoms or electrons to neutralize reactive oxygen species, chelate pro-oxidant metal ions, and inhibit cyclooxygenase and lipoxygenase enzymes that drive inflammatory arachidonic acid metabolism. β-Myrcene and geraniol additionally modulate central nervous system activity through proposed interactions with GABA-A receptors, contributing to observed anxiolytic and antinociceptive effects in rodent models.

Scientific Research

The preponderance of evidence for Cymbopogon citratus derives from in vitro antimicrobial and antioxidant assays and animal pharmacology studies, with no registered large-scale human randomized controlled trials identified in the current literature. In vitro studies have quantified citral's antifungal potency with rigorous MIC and IC₅₀ determinations across multiple fungal species, and extraction optimization studies have reproducibly characterized polyphenol yields (TPC up to 71.98 ± 0.33 mg GAE/100 mL) and radical-scavenging capacity under defined conditions. Ethnopharmacological surveys document consistent traditional use for digestive, anxiolytic, and antihypertensive purposes across Pacific Island and African populations, lending biological plausibility to preclinical findings. Overall, the evidence base is preclinical in nature; human pharmacokinetic, dose-response, and efficacy trial data are largely absent, placing confidence in clinical translation at a low-to-moderate level.

Clinical Summary

No prospective human clinical trials with defined sample sizes, randomization, or reported effect sizes have been identified specifically for Cymbopogon citratus as a supplement or tea for any indication. Preclinical in vitro data robustly demonstrate antifungal and antioxidant activity with quantified IC₅₀ and FRAP values, and animal studies support anxiolytic and antinociceptive effects, but these outcomes have not been translated into controlled human studies. Traditional use in Pacific Island communities—particularly Samoan and Tongan tea preparations for stomachache—represents ethnopharmacological evidence that informs biological plausibility but cannot substitute for clinical trial data. Confidence in clinical efficacy remains low pending human trials, and all current therapeutic claims are extrapolated from preclinical or traditional sources.

Nutritional Profile

Lemongrass contains approximately 8.40% crude protein and 8.06% ash (indicating significant mineral content including calcium, phosphorus, iron, and magnesium) on a dry-weight basis. The essential oil fraction comprises up to 80% citral (as geranial and neral isomers), with secondary volatiles including geraniol, geranyl acetate, citronellal, β-myrcene, limonene, borneol, and germacrene-D. Phenolic content in optimized water extracts reaches 71.98 ± 0.33 mg GAE/100 mL, with caffeic acid (20.81 ± 0.003 mg/100 mL) and syringic acid (18.63 ± 7.390 mg/100 mL) as dominant phenolic acids, and flavonoids including quercetin, luteolin, apigenin, isoorientin 2'-O-rhamnoside, and kaempferol present in lower concentrations. Bioavailability of citral from aqueous tea preparations is likely limited due to its hydrophobic nature; emulsification or consumption with dietary fat may enhance absorption, though no formal human bioavailability studies have been conducted.

Preparation & Dosage

- **Traditional Aqueous Decoction (Tea)**: 1.22–5 g dried lemongrass powder or chopped stalks per 100 mL water, heated to approximately 93.8°C for 11.3 minutes to maximize total polyphenol content (up to 71.98 mg GAE/100 mL); consumed for stomachache in Samoan and Tongan practice.
- **Essential Oil (Aromatherapy/Topical)**: Steam-distilled oil standardized to ≥70% citral content; used topically in diluted form (1–2% in carrier oil) or via inhalation diffusion—no standardized oral supplemental dose established.
- **Dried Herb / Capsule**: Commercial preparations typically 400–500 mg dried herb per capsule; standardization to citral percentage is not yet industry-standard, limiting dose consistency.
- **Methanol/Ethanol Extract**: Research extracts yield 16.56 ± 0.05 mg GAE/g dry weight total polyphenols; equivalent standardized supplement doses have not been established in clinical trials.
- **Timing**: Traditional tea is consumed after meals for digestive complaints; no pharmacokinetic data exist to support specific timing recommendations for supplemental forms.

Synergy & Pairings

Lemongrass essential oil demonstrates enhanced antifungal activity when combined with other terpenoid-rich oils such as tea tree (Melaleuca alternifolia) or thyme (Thymus vulgaris), where membrane-disrupting mechanisms of citral and thymol act additively or synergistically against Candida species. The antioxidant phenolics in lemongrass—caffeic acid and quercetin—may synergize with vitamin C (ascorbic acid) through phenolic radical regeneration cycles, collectively increasing overall radical-scavenging capacity beyond either agent alone. In Pacific Island traditional practice, lemongrass is sometimes combined with ginger (Zingiber officinale) in digestive teas, pairing the spasmolytic terpenoids of lemongrass with ginger's 6-gingerol-mediated 5-HT3 antagonism for complementary gastrointestinal relief.

Safety & Interactions

At typical culinary and traditional tea doses, lemongrass is generally regarded as safe; however, formal clinical safety studies in humans are absent, and the existing literature does not report systematic adverse event data. High-dose or concentrated essential oil ingestion poses a theoretical risk of mucous membrane irritation and hepatotoxicity given citral's reactive aldehyde chemistry, particularly at supplemental doses exceeding traditional culinary quantities. No specific drug interaction studies have been conducted, but citral's potential to modulate cytochrome P450 enzyme activity—observed for structurally related monoterpenes—raises theoretical concern for interactions with anticoagulants, antihypertensives, and sedative medications. Lemongrass essential oil is contraindicated in pregnancy at medicinal doses due to potential uterotonic effects observed in animal studies, and both the herb and oil should be used cautiously during lactation in the absence of safety data.